BACKGROUND: Tumor vascularity is an independent predictor of prognosis in HCC patients, however, the growth factors governing the angiogenesis remain obscure. MATERIALS AND METHODS: Multiple mRNA species of angiogenesis-related growth factors/receptors and CD31 were evaluated in 38 hepatocellular carcinomas (HCCs) and surrounding livers (SL) by a highly sensitive RNase protection assay. RESULTS: Significant increases in VEGF, VEGFR3, endoglin and CD31 mRNA expressions were noted in HCC rather than in SL. Only VEGFR1 had significant correlation with CD31 expression. VEGFRs and CD31 overexpressed in tumors with portal vein invasion and only VEGFR3- and CD31-positive patients had significantly shorter disease-free survival. Tie1 and Tie2 were overexpressed in large HCCs. The VEGF and Tie receptors expressed differentially in 28 tumors. CONCLUSION: The VEGF receptors might play the major role in HCC angiogenesis and prognosis. The differential expression of receptors might prove valuable in selected subsets of patients for tailored antiangiogenic therapy in HCC patients.
BACKGROUND: Tumor vascularity is an independent predictor of prognosis in HCC patients, however, the growth factors governing the angiogenesis remain obscure. MATERIALS AND METHODS: Multiple mRNA species of angiogenesis-related growth factors/receptors and CD31 were evaluated in 38 hepatocellular carcinomas (HCCs) and surrounding livers (SL) by a highly sensitive RNase protection assay. RESULTS: Significant increases in VEGF, VEGFR3, endoglin and CD31 mRNA expressions were noted in HCC rather than in SL. Only VEGFR1 had significant correlation with CD31 expression. VEGFRs and CD31 overexpressed in tumors with portal vein invasion and only VEGFR3- and CD31-positive patients had significantly shorter disease-free survival. Tie1 and Tie2 were overexpressed in large HCCs. The VEGF and Tie receptors expressed differentially in 28 tumors. CONCLUSION: The VEGF receptors might play the major role in HCC angiogenesis and prognosis. The differential expression of receptors might prove valuable in selected subsets of patients for tailored antiangiogenic therapy in HCC patients.
Authors: Bachir Taouli; R Scott Johnson; Cristina H Hajdu; Marcel T H Oei; Miriam Merad; Herman Yee; Henry Rusinek Journal: AJR Am J Roentgenol Date: 2013-10 Impact factor: 3.959
Authors: Evan Delgado; Raman Bahal; Jing Yang; Jung M Lee; Danith H Ly; Satdarshan P S Monga Journal: Curr Cancer Drug Targets Date: 2013-10 Impact factor: 3.428
Authors: Nicole L Ward; Alexandra L Haninec; Paul Van Slyke; John G Sled; Celina Sturk; R Mark Henkelman; Ian R Wanless; Daniel J Dumont Journal: Am J Pathol Date: 2004-09 Impact factor: 4.307